N-Cadherin Expression Is Associated with Acquisition of EMT Phenotype and with Enhanced Invasion in Erlotinib-Resistant Lung Cancer Cell Lines

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Zhang, Xiaoju ^a   Liu, Guangzhi ^a   Kang, Yi ^a   Dong, Zhaogang ^b   Qian, Qiyu ^a   Ma, Xitao ^a  

^a HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; NERVE CELL ADHESION MOLECULE; SMALL INTERFERING RNA; UVOMORULIN; VIMENTIN;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER RESISTANCE; CELL ASSAY; CELL PROLIFERATION; CELL STRAIN H1650; CELL STRUCTURE; CLINICAL ARTICLE; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER; MALE; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; TISSUE SECTION; TUMOR BIOPSY; UPREGULATION; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; ANTIGENS, CD; CADHERINS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; UP-REGULATION;

EID: 84874764881     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057692     Document Type: Article

References (41)

1. Spira A, Ettinger DS, (2004) Multidisciplinary management of lung cancer. N Engl J Med 350: 379-92.
2. Carney DN, (2002) Lung cancer-time to move on from chemotherapy. N Engl J Med 346: 126-8.
3. Friedel G, Budach W, Dippon J, Spengler W, Eschmann SM, et al. (2010) Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. J Clin Oncol 28: 942-8.
4. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med 350: 2129-2139.
5. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
6. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U.S.A 101: 13306-13311.
7. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, (2009) et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361: 947-957.
8. Bean J, Brennan C, Shih JY, Riely G, Viale A, et al. (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.Proc. Natl. Acad. Sci. U.S.A. 104: 20932-20937.
9. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, et al. (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with asecond mutation in the EGFR kinase domain. PLoS Med. 2: 73.
10. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, et al. (2007) MET amplification leads to gefitinib resistancein lung cancer by activating ERBB3 signaling. Science 316: 1039-1043.
11. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, et al. (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352: 786-792.
12. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, (2008) et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancercells is mediated by loss of IGF-binding proteins. J. Clin. Invest. 118: 2609-2619.
13. Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, et al. (2010) Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 29: 2346-2356.
14. Engelman JA, Jänne PA, (2008) Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 14: 2895-2899.
15. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, et al. (2010) Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17: 77-88.
16. Guo A, Villén J, Kornhauser J, Lee KA, Stokes MP, et al. (2008) Signaling networks assembled by oncogenic EGFR and c-met. Proc Natl Acad Sci USA 105: 692-7.
17. Thomson S, Buck E, Petti F, Griffin G, Brown E, et al. (2005) Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65: 9455-9462.
18. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, et al. (2007) Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol. Cancer Ther 6: 1683-1691.
19. Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, et al. (2006) Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 4: 521-528.
20. Fuchs BC, Fujii T, Dorfman JD, Goodwin JM, Zhu AX, et al. (2008) Epithelial-to-mesen chymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res 68: 2391-2399.
21. Rho JK, Choi YJ, Lee JK, Ryoo BY, Na II, et al. (2009) Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63: 219-226.
22. Gumbiner BM, (2005) Regulation of cadherinmediated adhesion in morphogenesis. Nat Rev Mol Cell Biol 6: 622-634.
23. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, et al. (2003) Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144: 1032-44.
24. Thomson S, Buck E, Petti F, Griffin G, Brown E, et al. (2005) Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 65: 9455-9462.
25. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, et al. (2005) Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11: 8686-8698.
26. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR, (2008) Cadherin switching. J Cell Sci 121: 727-735.
27. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, et al. (2000) Cadherin switching in human prostate cancer progression. Cancer Res 60: 3650-3654.
28. Kase S, Sugio K, Yamazaki K, Okamoto T, Yano T, et al. (2000) Expression of E-cadherin and beta-catenin in human non-small cell lung cancer and the clinical significance. Clin Cancer Res 6: 4789-4796.
29. Bremnes RM, Veve R, Hirsch FR, Franklin WA, (2002) The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer 36: 115-124.
30. Tran NL, Adams DG, Vaillancourt RR, Heimark RL, (2002) Signal transduction from N-cadherin increases Bcl-2. Regulation of the phosphatidylinositol 3-kinase/Akt pathway by homophilic adhesion and actin cytoskeletal organization. J Biol Chem 277: 32905-32914.
31. Mariotti A, Perotti A, Sessa C, Ruegg C, (2007) N-cadherin as a therapeutic target in cancer. Expert Opin Investig Drugs 16: 451-465.
32. Yamauchi M, Yoshino I, Yamaguchi R, Shimamura T, Nagasaki M, et al. (2011) N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells.Am J Cancer Res. 1: 823-33.
33. Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, et al. (2012) Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther 11: 2149-57.
34. Cha MY, Lee KO, Kim M, Song JY, Lee KH, et al. (2012) Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer 130: 2445-54.
35. Suda K, Tomizawa K, Fujii M, Murakami H, Osada H, et al. (2011) Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib. J Thorac Oncol 6: 1152-61.
36. Ciołczyk-Wierzbicka D, Gil D, Laidler P, (2012) The inhibition of cell proliferation using silencing of N-cadherin gene by siRNA process in human melanoma cell lines.Curr Med. Chem19: 145-51.
37. Nalla AK, Estes N, Patel J, Rao JS, et al. (2011) N-cadherin mediates angiogenesis by regulating monocyte chemoattractant protein-1 expression via PI3K/Akt signaling in prostate cancer cells.Exp Cell Res. 317: 2512-21.
38. Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, et al. (2011) Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Adv Med Sci 56: 275-84.
39. Rebucci M, Peixoto P, Dewitte A, Wattez N, De Nuncques MA, et al. (2011) Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance. Int J Oncol 38: 189-200.
40. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, et al. (2010) Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med 16: 1414-20.
41. Wallerand H, Cai Y, Wainberg ZA, Garraway I, Lascombe I, et al. (2010) Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines. Urol Oncol 28: 180-8.